Sunitinib
Sutent
Sources
fda, as of 2026-11-07
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43a4d7f8-48ae-4a63-9108-2fa8e3ea9d9c
Time-to-tumor progression [median, weeks (95% CI)] 27.3 (16.0, 32.1) 6.4 (4.4, 10.0) ... Progression-free survival [median, weeks] 24.1 (11.1, 28.3) 6.0 (4.4, 9.9) ... Objective response rate (PR) 6.8 ... 0
Sutent USPI boxed warning (hepatotoxicity) and section 14.1, Table 10, Study 1 (NCT00075218)
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT00075218
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of SU011248 In The Treatment Of Patients With Imatinib Mesylate (Gleevec Tm, Glivec)-Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor
ClinicalTrials.gov API v2 record, retrieved 2026-11-07